Ingalls & Snyder LLC Purchases New Position in iShares Biotechnology ETF (NASDAQ:IBB)

Ingalls & Snyder LLC acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,599 shares of the financial services provider’s stock, valued at approximately $233,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new position in shares of iShares Biotechnology ETF during the third quarter worth $29,000. Highline Wealth Partners LLC bought a new stake in iShares Biotechnology ETF during the 3rd quarter worth $30,000. Bbjs Financial Advisors LLC acquired a new position in iShares Biotechnology ETF in the 2nd quarter worth about $31,000. Ashton Thomas Securities LLC bought a new position in iShares Biotechnology ETF in the third quarter valued at about $36,000. Finally, Voisard Asset Management Group Inc. acquired a new stake in shares of iShares Biotechnology ETF during the third quarter valued at about $59,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ:IBB opened at $140.00 on Wednesday. The stock’s 50-day moving average is $142.63 and its 200-day moving average is $142.12. iShares Biotechnology ETF has a 1-year low of $121.84 and a 1-year high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were issued a dividend of $0.2005 per share. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.